Genmab A/S (GMAB)
| Market Cap | 23.56B |
| Revenue (ttm) | 2.39B |
| Net Income (ttm) | 693.28M |
| Shares Out | 653.13M |
| EPS (ttm) | 1.03 |
| PE Ratio | 37.63 |
| Forward PE | 35.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,255 |
| Open | 36.24 |
| Previous Close | 36.49 |
| Day's Range | 35.98 - 36.42 |
| 52-Week Range | 31.40 - 47.50 |
| Beta | 0.66 |
| Analysts | Buy |
| Price Target | 43.00 (+19.18%) |
| Earnings Date | Nov 8, 2023 |
About GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL a... [Read more]
Financial Performance
In 2022, Genmab's revenue was 14.60 billion, an increase of 72.07% compared to the previous year's 8.48 billion. Earnings were 5.52 billion, an increase of 83.58%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $43.0, which is an increase of 19.18% from the latest price.
News
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 12, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,356 shares as a consequence of the exercise of employee warrants. The in...
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results
Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% announced that Tivdak, their treatment for cervical ...
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint
Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-line therapy met its primary endpoint of overall sur...
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic ce...
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic ce...
Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will p...
Genmab Announces Financial Results for the First Half of 2023
August 3 , 202 3 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023
Genmab Updates 2023 Financial Guidance
Company Announcement COPENHAGEN , Denmark; July 2 8 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB) announced today its preliminary first half 2023 financial results and its updated 2023 financial guidance. Pr...
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive ...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
Company Announcement Net sales of DARZALEX ® in the second quarter of 202 3 totaled USD 2,431 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, ...
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
- Based on the topline results of epcoritamab from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities to discuss next steps - Additional data from the clin...
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE™ NHL-1 clinical...
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas'
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network® (N...
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody adm...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN , Denmark; June 8 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB) announced today that the B oard decided to grant 7,825 restricted stock units and 8,106 warrants to employees o...
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44 th...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; June 1, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this d...
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; May 31, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this d...
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Soci...
US FDA approves Genmab-AbbVie's blood cancer therapy
The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment...
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell e...
Genmab Announces Financial Results for the First Quarter of 2023
May 10 , 202 3 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
Company Announcement C OPENHAGEN , Denmark; April 24 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second a...
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
Company Announcement COPENHAGEN , Denmark; April 21 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, ...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
Company Announcement Net sales of DARZALEX ® in the first quarter of 202 3 totaled USD 2,264 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, D...